T/CACM 1318.19-2019 Digestive System Common Diseases: Traditional Chinese Medicine Guideline Part 19: Irritable Bowel Syndrome (Basic Level Physician Version)

Scope

Main technical content: Irritable bowel syndrome (IBS) is a common disease worldwide. According to the Rome II criteria, the prevalence of IBS in Beijing and Guangzhou was 0.82%[1] and 5.67%[2], respectively. A meta-analysis showed that the overall prevalence of IBS in the Chinese population was 6.5%. Although IBS does not have a significant impact on patients' overall health and life expectancy, patients often visit hospitals frequently due to long-term recurring symptoms, delayed diagnosis, and unsatisfactory treatment outcomes, which seriously affect their quality of life and impose corresponding economic and social burdens[3]. From the perspective of modern medicine, there are still some deficiencies in the treatment of this disease, and the long-term therapeutic effect is still unsatisfactory. Traditional Chinese medicine (TCM) has a long history in treating similar symptoms of IBS. Due to the characteristics of TCM itself and the individualized nature of treatment, it is difficult to obtain high-level evidence-based medicine evidence for its clinical efficacy evaluation, but its clinical efficacy should be confirmed. Currently, the existing consensus on IBS in China mainly targets tertiary-level hospitals, and the clinical use and recommendations of TCM are described relatively briefly. This guideline is mainly aimed at grassroots-level doctors. Based on literature collection and evidence evaluation, combined with expert consensus, this guideline provides recommendations, hoping to improve the level of TCM prevention and treatment of this disease among grassroots-level doctors.

Development Information

Same series standard

Related Standards